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Abstract
A safe and effective vaccine against human immunodeficiency vi-
rus type 1 (HIV-1) is urgently needed to combat the worldwide 
AIDS pandemic, but still remains elusive. The fact that uncon-
trolled replication of an attenuated vaccine can lead to regain-
ing of its virulence creates safety concerns precluding many vac-
cines from clinical application. We introduce a novel approach to 
control HIV-1 replication, which entails the manipulation of es-
sential HIV-1 protein biosynthesis through unnatural amino acid 
(UAA*)-mediated suppression of genome-encoded blank codon. 
We successfully demonstrate that HIV-1 replication can be pre-
cisely turned on and off in vitro.
Keywords: attenuated vaccine,  genetic code expansion, HIV-1 
vaccine, unnatural amino acid, virus engineering
Genetic code expansion with the evolved orthogonal 
suppressor tRNA–aminoacyl-tRNA synthetase (aaRS) pair 
has been widely applied to site-specific incorporation of 
unnatural amino acids (UAA*s) with unique chemical and 
physical properties into proteins in living cells to facilitate 
the study of protein structure and function.[1] Here we re-
port a new application of genetic code expansion, which 
couples the UAA*-mediated blank codon (codon that does 
not encode natural proteinogenic amino acids) suppression 
with the virus assembly process for a potential solution to 
the development of a live-attenuated HIV-1 vaccine. In this 
strategy, the replication of HIV-1 is controlled by UAA*s 
that are not present in nature and constitute unique chemi-
cal probes for future immunological studies.
The search for safe and effective HIV-1 preventive vac-
cines has been ongoing for more than 30 years since HIV-1 
was identified as the causative agent for AIDS.[2] Unfor-
tunately, safe and effective HIV-1 vaccines remain elu-
sive.[2b, 3] More than 60 million people worldwide have 
been infected with HIV-1 and nearly half of these individ-
uals have died. Although progress has been made in pre-
venting new HIV-1 infections and in lowering the annual 
number of AIDS-related deaths through comprehensive 
prevention programs and increased access to antiretro-
viral therapy,[2b] the number of people living with HIV-1, 
now over 34 million, continues to grow. The development 
of a safe and effective HIV-1 vaccine would undoubtedly 
be one of the best solutions for the ultimate control of the 
worldwide AIDS pandemic.[4] One visible achievement of 
the past few years was the results of the RV144 trial—the 
HIV-1 vaccine trial conducted in Thailand—which showed 
that a poxvirus-protein prime-boost combination pro-
vided modest (31%) protection against HIV-1 acquisition.[5] 
These results represent the first demonstration of any level 
of efficacy in preventing HIV-1 acquisition in humans by 
a vaccine. However, the low level of protection elicited by 
RV144 vaccine makes this vaccine not useful in clinic. Of 
all the HIV-1 vaccine modalities developed and tested thus 
far, deletion of nef gene in HIV-1 as a live-attenuated vac-
cine (Δnef-LAV) has shown the best efficacy against HIV-1 
acquisition (Δnef-LAV protection rate is 95%versus 7%for 
all other types of vaccines) in SIV/ rhesus macaque model 
of HIV-1 infection.[6] Despite its best efficacy, the current 
version of this live-attenuated HIV- 1 vaccine cannot be de-
veloped for clinical use due to safety concerns. Therefore, 
finding a safe and effective HIV- 1 vaccine using novel ap-
proaches remains a top priority.
We sought to solve the safety problem by turning vi-
rus replication on and off using the UAA*-mediated blank 
codon suppression system (Figure 1).[1b,c, 7] We envis-
aged that if we could introduce blank codons at positions 
within the HIV- 1 genome (such as the Δnef-LAV) that en-
code essential proteins, we would prevent proper trans-
lation and assembly of viable HIV-1. On the other hand, 
live and functional HIV-1 can be assembled in the pres-
ence of a special tRNA–aaRS pair that could decode the 
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Figure 1. Construction of novel live-attenuated HIV vaccine through genetic 
code expansion. UAA*, unnatural amino acid.
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blank codon. The assembled HIV-1 can be subsequently 
used as a live-attenuated vaccine. Since the host does not 
contain the special tRNA–aaRS pair, HIV-1 can only un-
dergo one-cycle infection and is not able to replicate, thus 
making the vaccine safer. To render the system more strin-
gent, special tRNA–aaRS pairs that only recognize desired 
UAAs* (the host lacks these UAAs*) are used. The UAA*-
mediated blank codon suppression would also allow us to 
turn on and off multiple replication cycles of HIV-1 in vivo 
using UAA* as the control element in future vaccine devel-
opment. Here we report a successful demonstration of con-
trolling HIV-1 replication in vitro.
Two systems, E. coli tRNATyr–tyrosyl-tRNA synthetase 
(TyrRS) pair and archaeal tRNAPyl–pyrrolysyl-tRNA syn-
thetase (PylRS) pair, have been developed to decode ei-
ther nonsense[8] or frameshift[9] codons in mammalian 
cells. However, the complicated assembly process of hu-
man viruses makes it very challenging to genetically in-
corporate UAA* into proteins in live human viruses us-
ing the above two systems. During our HIV-1 studies, 
Chen and co-workers reported the first site-specific incor-
poration of UAA* into surface proteins of hepatitis D vi-
rus using the tRNAPyl–PylRS pair.[10] In this work, we fo-
cus on the E. coli tRNATyr–TyrRS pair, and specifically on 
the tRNATyr–4-azidophenylalanyltRNA synthetase (Az-
FRS), tRNATyr–4-acetylphenylalanyltRNA synthetase (Ac-
FRS), and tRNATyr–4-iodophenylalanyl- tRNA synthetase 
(IodoFRS) pairs.[8a] Since these three amino acids have sim-
ilar size to tyrosine, we envisaged that the incorporation of 
these three amino acids will unlikely have detrimental ef-
fects on the function of HIV-1 proteins. AzF and AcF (Fig-
ure 2A) also contain unique functional groups that allow 
selective modification of viral proteins through bioorthog-
onal reactions, which is expected to facilitate future studies 
on viral replications and immunological evaluation of vac-
cine candidates. The recent development of tRNAPyl–PylRS 
pair may also allow us to conservatively replace lysine res-
idues with pyrrolysine analogues in future vaccine studies.
To examine the amber suppression efficiency and 
fidelity of the tRNATyr–AzFRS pair, 293T cells were co-
transfected with a plasmid containing tRNATyr under the 
control of a human U6 promoter and AzFRS (pAzFRS) 
with a plasmid encoding enhanced green fluorescent pro-
tein (EGFP) with an amber mutation at residue 40 (pEGFP-
TAG40). Following transfection, cells were cultured in 
DMEM media (containing 10%fetal bovine serum (FBS) 
and 2 mml-glutamine) with or without 1 mm AzF for 12 h 
before visualization under a fluorescence microscope (Fig-
ure 2C,D). Full-length EGFP was detected only in cells sup-
plemented with 1 mm AzF (Figure 2C), while no EGFP was 
observed otherwise (Figure 2D). The tandem mass spec-
trometry data (Figure S4 in the Supporting Information) 
showed no undesirable incorporation of tyrosine or any 
other natural amino acids. The amber mutation site con-
tained exclusively 4-aminophenylalanine (aminoF), which 
is the reduction product of AzF. This observation is consis-
tent with previous reports on mass spectrometry analyses 
of AzF-containing proteins.[8a, 11] The above results confirm 
an excellent fidelity of AzF incorporation.
We then went on to test the suppression of an amber co-
don on HIV-1 genome (pSUMA.c/2821, cat#11748, the in-
fectious molecular clone of a founder/transmitter HIV- 1 
virus from Dr. John Kappes and Dr. Christina Ochsenbauer 
through the NIH AIDS Reagent Program, Division of 
AIDS, NIAID, NIH; abbreviated hereafter as pSUMA). We 
first chose to mutate the Tyr132 codon on the Gag (group-
specific antigen) protein-encoding gene into an amber co-
don. The resulting pSUMA-Tyr132 was co-transfected 
into 293T cells with plasmid pAzFRS. After the cells were 
grown for 48 h in the presence and the absence of 1 mm 
AzF, viruses were harvested and the titer of HIV-1 was 
analyzed using anti-p24 antibody. The presence and the 
strength of a blue color suggest the presence and the level 
of the capsid protein p24. As shown in Figure 3A (wells 
3 and 4), we observed an AzFdependent p24 synthesis in 
pSUMA-Tyr132 mutant due to the essential role of Gag 
(Gag is processed during maturation to p24) in p24 protein 
synthesis. The p24 assay confirmed a very high fidelity of 
AzF incorporation (absorbance values of 0.001 versus 0.453 
in the absence and the presence of AzF, respectively; Fig-
ure 3A, wells 3 and 4). However, only very low level of p24 
synthesis was observed compared to the wildtype pSUMA 
control (Figure 3A, well 1). On the other hand, very strong 
p24 synthesis was observed with the tRNATyr–AcFRS pair 
(Figure S1, well 4) and an undetectable p24 synthesis was 
observed with the tRNATyr–IodoFRS pair (Figure S1, well 
7). Despite amber suppression and the synthesis of p24, un-
fortunately, no viral infection was observed when the har-
vested viruses were used to infect TZM-bl cells (Figure 3D 
and Figure S2A,D). (The TZM-bl cell line stably expresses 
large amounts of CD4 and CCR5 and should be highly sen-
sitive to infections by diverse isolates of HIV-1. The TZMbl 
also contains a genome copy of b-galactosidase gene under 
the control of the HIV-1 promoter. The infection assay is 
based on the expression level of b-galactosidase.)
To explain the lack of live HIV-1 assembly from the 
above experiments, we first examined whether amber sup-
pression can negatively affect HIV- 1 protein syntheses, 
Figure 2. Controlled EGFP expression in 293T cells. (A) Chemical struc-
tures of 4- azidophenylalanine (AzF), 4-acetylphenylalanine (AcF), and 4-io-
dophenylalanine (IodoF). (B) EGFP with an Amber codon at position 40. (C) 
EGFP expression in the presence of the tRNATyr–AzFRS pair and 1 mm of 
AzF. (D) EGFP expression in the presence of the tRNATyr–AzFRS pair, but 
without AzF. Scale bars, 200 mm.
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virion assembly, and/or infection since HIV-1 uses seven 
amber codons as stop signal. To this end, wild-type 
pSUMA was co-transfected with plasmid pAzFRS into 
293T cells. After 48 h of cultivation in the presence of 1 
mm AzF, viruses were harvested and the titer of HIV-1 
was analyzed using anti-p24 antibody. We observed no ob-
vious difference in p24 synthesis (Figure 3A, wells 1 and 
2) and infection rate (Figure 3B,C) of wild-type pSUMA 
in the presence or the absence of the amber suppressing 
tRNATyr–AzFRS pair. To further eliminate the possibility, 
we constructed a different HIV-1 mutant that was derived 
from pNL-GI,[12] which contains a copy of GFP inserted at 
the nef locus. In this new HIV-1 construct, an amber muta-
tion was made at position 40 of GFP (originally encode a 
tyrosine residue) and there was no amber mutation on the 
HIV-1 protein-encoding genes. The resulting HIV-1 vari-
ant, pNL-GI-Tyr40, was transfected into 293T cells together 
with plasmid pAzFRS. Strong GFP fluorescence (Figure 4B) 
was detected when 1 mm of AzF was included in the cul-
ture medium. The fluorescence intensity is comparable to 
the wild-type pNL-GI (Figure 4A), which indicated a very 
efficient amber suppression with the tRNATyr–AzFRS pair. 
The produced HIV-1 viruses were then harvested and used 
to infect TZM-bl cells. Near wild-type infection was ob-
served (Figure 4C,D). Based on the above observations, we 
concluded that amber suppression does not have detect-
able detrimental effects on the viability of HIV-1.
We then tested if UAA* incorporation at Tyr132 of Gag 
protein interfered with either the proper function or the 
posttranslational processing of the Gag protein. To this 
end, the pSUMA-Tyr132 mutant was transfected into 293T 
cells with a plasmid containing tRNATyr–TyrRS pair. The 
amber suppression led to the incorporation of a tyrosine 
residue at position 132, which produced the wild-type Gag 
protein. The p24 (Figure 3A, well 5) and infection (Figure 
3F) assays showed that the pSUMA-Tyr132 mutant, after 
amber suppression, had near wild-type activities. As a con-
trol, when pSUMA-Tyr132 was transfected into 293T cells 
that did not contain the tRNATyr–TyrRS pair, no p24 syn-
thesis was detected (Figure 3A, well 6) and no live viruses 
were assembled according to the infection assay (Figure 
3G). Combining these results and the results from UAA* 
incorporation, we concluded that incorporation of UAA* at 
position Tyr132 must have a negative effect on Gag protein 
expression and/or function.
We next decided to examine other mutation sites and 
generated two new HIV-1 mutants, with amber muta-
tion at Ala119 of Gag (pSUMA-Ala119) and Leu365 of Pol 
(pSUMA-Leu365), respectively. We initially focused on 
the amber suppression with the tRNATyr–AzFRS pair in 
the presence of AzF. We observed an AzF-dependent p24 
synthesis in pSUMA-Ala119 (Figure 3A, wells 7 and 8). 
The amber suppression at Ala119 position (Figure 3Awell 
8) was apparently stronger than that at position Tyr132 of 
Figure 3. Control HIV-1 replication with Amber suppression. A) p24 assay 
after transfection of 293T with pSUMA variants. The absorbance values were 
determined at 450 nm after the colorimetric reactions were stopped by the 
addition of 1m H2SO4. The well 11 was used as blank for all measurements. 1, 
wild-type pSUMA only; 2, wild-type pSUMA + tRNATyr–AzFRS pair + 1 mm 
AzF; 3, pSUMA-Tyr132 + tRNATyr–AzFRS pair, without AzF; 4, pSUMA-Tyr132 
+ tRNATyr–AzFRS pair, with 1 mm AzF; 5, pSUMA-Tyr132 + tRNATyr–TyrRS 
pair; 6, pSUMA-Tyr132; 7, pSUMA-Ala119 + tRNATyr–AzFRS pair, without 
AzF; 8, pSUMA-Ala119 + tRNATyr-AzFRS pair, with 1 mm AzF; 9, pSUM-
ALeu365+ tRNATyr-AzFRS pair, without AzF; 10, pSUMA-Leu365+tRNATyr- 
AzFRS pair, with 1 mm AzF; 11, negative ELISA control, no p24; 12, positive 
ELISA control, 125 pgmL×1 p24; (B)–(I) Infection assays with TZM-bl cells: (B) 
infected with virus collected from (A-1); (C) infected with virus collected 
from (A-2); (D) infected with virus collected from (A-4); (E) infected with vi-
rus collected from (A-3); (F) infected with virus collected from (A-5); (G) in-
fected with virus collected from (A-6); (H) infected with virus collected from 
(A-8); (I) infected with virus collected from (A-10). Scale bars, 100 mm.
Figure 4. Expression and infection with pNL-GI variants. (A) Fluorescence 
image of pNL-GI. (B) Fluorescence image of pNL-GI-Tyr40 + tRNATyr-AzFRS 
pair, with 1 mm AzF. (C) TZM-bl cell infection with virus collected from (A). 
(D) TZM-bl cell infection with virus collected from (B). Scale bars, 200 mm.
4870 N. W a N g ,  Y.  L i ,  e t  a L .  i N  A n g e w A n d t e  C h e m i e  i n t e r n A t i o n A l  e d i t i o n  53  (2014) 
Gag (Figure 3A well 4) and has similar good fidelity (absor-
bance values of 0.000 versus 2.127 in the absence and the 
presence of AzF, respectively; Figure 3A, wells 7 and 8). On 
the other hand, the synthesis of p24 in pSUMA-Leu365 was 
not AzF dependent (Figure 3A, wells 9 and 10) since the 
amber mutation is in Pol, which does not affect p24 synthe-
sis. Both mutants showed infection (Figure 3H,I) but with 
much lower activity than wild-type pSUMA (Figure 3B). 
As a control, no infection was observed when AzF was not 
provided in the culture medium of 293T cells after transfec-
tion (Figure S3A,B). We next examined the tRNATyr–AcFRS 
pair and tRNATyr–IodoFRS pair. As shown in Figure S1, a 
range from nondetectable to relative strong amber suppres-
sion was observed with the two tRNA–aaRS pairs and the 
different amber mutation sites (Figure S1, wells 5, 6, 8, and 
9). However, no infection was detected when tRNATyr–Ac-
FRS pair and tRNATyr–IodoFRS pair were used to gener-
ate pSUMA-Ala119 and pSUMA-Leu365 mutants (Figure 
S2B,C,E,F). Since the amber suppression efficiency did not 
correlate well with the infection results, we suspected that 
the structure of UAA*s and the incorporation sites might 
still partially interfere with the protein function.
An additional mutation site, Tyr59TAG (pSUMA-Tyr59) 
of HIV-1 protease was then examined. Since Tyr59 has sim-
ilar structure to AzF and is away from the active site (PDB 
1EBZ),[13] mutation of Tyr59 to AzF might not cause unde-
sired disturbance of protein structure and function. Indeed, 
the pSUMA-Tyr59 mutant showed better infection activity 
(Figure 5B) than pSUMA-Ala119 (Figure 3H) and pSUMA-
Leu365 (Figure 3I). As a control, no live pSUMATyr59 virus 
was produced in the absence of AzF during viral assembly 
in 293T cells according to the infection assay (Figure S3C). 
A comparison between the observed tissue culture infec-
tious dose 50 (TCID50) values in the presence (1.31 × 103) 
and the absence of AzF (0.00) implicates high fidelity of the 
tRNATyr–AzFRS pair. But the amber suppression efficiency 
still needs further improvement in order to obtain better ti-
ter of live HIV-1 mutants. Nonetheless, the above results 
suggest that the UAA*-mediated amber suppression strat-
egy can be used to produce live HIV-1 and the resulting vi-
rus is infectious. Since the infected cells do not contain the 
amber suppression machinery (the special tRNA–aaRS pair 
and UAA*) that is required for HIV-1 assembly, no new vi-
rus can be assembled after the initial infection.
While the fidelity of UAA* incorporation is very good 
with a comparable fidelity of protein synthesis in nature, it 
remains possible that the HIV-1 can regain functional rep-
lication by mutating amber codon back to a sense codon 
since HIV-1 has relatively high genetic variability. There-
fore, although we did not observe any case where the am-
ber codon was mutated back to sense codon under the cell 
culture conditions, such possibility might become greater 
in a longer time span or in vivo. We envisaged that the in-
troduction of multiple amber codons into the essential 
genes of HIV-1 could be used to further tighten the con-
trol on virus replication. If we take the virus mutation rate 
as approximately 3 × 10–5 per nucleotide base per cycle of 
replication[14] and the virus life cycle as one day, the possi-
bility of mutating all amber codons back to sense codons is 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
approximately 1% and 0.01%, respectively, during human 
life span (100 years) when one and two amber codons are 
used. Since the amber sites we chose are not in regions with 
high mutation rate, we expect a very low chance for HIV-1 
mutant to regain virulence if two or more amber codons are 
used. To examine if the suppression of two amber codons 
on the HIV-1 genome by the tRNATyr–AzFRS pair is effi-
cient enough to produce meaningful amounts of live HIV-1, 
we constructed an HIV- 1 mutant in which two amber mu-
tations, Trp36 and Gln127 of matrix domain (MA) of Gag 
(pSUMA-Trp36Gln127), were made according to the crys-
tal structure of the MA protein (PDB: 2H3F).[15] The Trp36 
and Gln127 are not key residues for MA×s interaction with 
phosphatidylinositol 4,5-bisphosphate.[15, 16] In addition, 
these mutation sites are located relative earlier on the HIV-1 
genome, which reduces the possibility of interference with 
the alternative reading frame and posttranslational process-
ing of HIV-1 proteins. Encouragingly, we observed simi-
lar infection activity with pSUMATrp36Gln127 (Figure 5C) 
compared to HIV-1 containing single amber mutation (Fig-
ure 5B). As a control, no live pSUMA-Trp36Gln127 virus 
was produced in the absence of AzF during viral assembly 
in 293T cells according to the infection assay (Figure S3D).
In conclusion, we have demonstrated that precise con-
trol of HIV-1 viability in vitro can be achieved by using a 
UAA*- mediated amber codon suppression strategy. The 
above work is an important step towards the develop-
ment of a safe and effective HIV-1 vaccine in order to com-
bat worldwide AIDS pandemic. Our approach can also be 
used to improve the safety of other live-attenuated or rep-
lication-competent vector-based vaccines. In addition, the 
ability to introduce unique functional groups into HIV-1 
proteins enables further modification of those proteins 
through bioorthogonal reactions, which could facilitate our 
future and other studies on HIV-1 in order to find a cure 
for HIV-1 related diseases.
Encouraged by our initial results, we are currently 
working on improving the efficiency of UAA*-mediated 
amber codon suppression. We are also constructing HIV-1 
mutants that contain genome insertion of either amber- 
or quadruplet-decoding tRNA-aaRS pair. These mutants 
will be examined for multi-cycle infection in vitro with the 
Figure 5. Infection assays with TZM-bl cells. (A) Infected with wild-type 
pSUMA. (B) Infected with pSUMA-Tyr59. (C) Infected with pSUMATrp-
36Gln127. Scale bars, 200 mm. The doses used for infection are shown as 
TCID50 values. The wild-type pSUMA was diluted 4-fold and the pSUMA 
mutants were concentrated 15-fold in order to adjust the infectious dose of 
each variant to similar levels.
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addition and the removal of UAA* as an on and off switch. 
Such manipulation will later allow us to control HIV-1 rep-
lication in humanized mouse for immunological evaluation 
of the vaccine candidates.[17]
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Supporting Information 
 
 
Material and Methods 
 
General.  All chemicals and DNA oligomers were obtained from commercial sources and used 
without further purification.  Unnatural amino acids (UAA*s), 4-azidophenylalanine (AzF) and 4-
iodophenylalanine (IodoF), are purchased from Bachem.  The synthesis of 4-
acetylphenylalanine (AcF) follows the procedure that was previously reported.[1]  HIV-1 clone, 
pSUMA, was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH, 
from Dr. John Kappes and Dr. Christina Ochsenbauer.  Standard molecular biology techniques 
(Sambrook et al., 2001) were used throughout.  E. coli DH10B and GeneHogs were used for 
routine cloning and DNA propagation.  E coli Stbl-2 (Life Technologies) was use for pSUMA 
manipulations. 
 
Plasmid construction   
pcDNA3.1-tRNATyr.  The amber suppressor tRNATyr was derived from E. coli.  The G35 of the 
tRNATyr was mutated to C to generate CUA anticodon.  The tRNATyr gene lacking 3’-CCA but 
with a 3’-TTTTTCT sequence was PCR amplified.  A human U6 promoter was PCR amplified 
from pCMV-pylRSNBK-1[2] and added in front of the tRNATyr gene by overlapping PCR.  The U6-
tRNATyr gene cassette was PCR amplified and inserted into pcDNA3.1/hygro(+, Life 
Technologies) in front of the CMV promoter to afford pcDNA3.1-tRNATyr.   
 
pAzFRS.  The AzFRS-encoding gene was PCR amplified from plasmid pSWAN-pAzpaRS[3] and 
inserted into pcDNA3.1-tRNATyr behind the non-regulated CMV promoter to afford plasmid 
pAzFRS. 
 
pAcFRS.  The AcFRS-encoding gene was PCR amplified from plasmid pSWAN-pApaRS[3] and 
inserted into pcDNA3.1-tRNATyr behind the non-regulated CMV promoter to afford plasmid 
pAcFRS. 
 
pIodoFRS.  The IodoFRS-encoding gene was PCR amplified from plasmid pSWAN-pIpaRS[3] 
and inserted into pcDNA3.1-tRNATyr behind the non-regulated CMV promoter to afford plasmid 
pIodoFRS. 
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pEGFP-TAG40.  The EGFP-encoding gene containing an amber stop codon (UAG) at a 
permissive site (Tyr40) was inserted into pcDNA3.1-tRNATyr behind the non-regulated CMV 
promoter to afford plasmid pEGFP-TAG40. 
 
pSUMA mutants.  Overlapping PCR was used to introduce amber mutations onto the HIV-1 
genome that is encoded by plasmid pSUMA.  The following primers are used to introduce 
amber mutations: 
 
pSUMA-Tyr132 
5’-CTAGAACGATTCGCAGTTAACCCTG-3’ 
5’-GTTCTGCACTATAGGCTAATTTTGGCTGACCTGGCTG-3’ 
5’-TAGCCTATAGTGCAGAACCTCCAG-3’ 
5’-GTGCCTATAGCTTTGTGTCCACAG-3’ 
 
pSUMA-Ala119 
5’-CTAGAACGATTCGCAGTTAACCCTG-3’ 
5’-TTTCCTGCGTCAGCctaTGCTTGCTGTGCTTTTTTCTTAC-3’ 
5’-CTGACGCAGGAAACAACAGCCAG-3’ 
5’-GTGCCTATAGCTTTGTGTCCACAG-3’ 
 
pSUMA-Leu365 
5’-CAAAGTAAGACAATATGATCAGGTAAC-3’ 
5’-CACCTCTACAGATGTTCTCTCAGTTCCTC-3’ 
5’-CATCTGTAGAGGTGGGGATTTACCACAC-3’ 
5’-GCTTCCCATGTTTCTCTTTGTATG-3’ 
 
pSUMA-Tyr59 
5’-CTAGAACGATTCGCAGTTAACCCTG-3’ 
5’-ATTTCTATGGTTACCTGATCCTATTGTCTTACTTTGATAAAAC-3’ 
 
pSUMA-Trp36Gln127 
5’-GTAGAGGATCCACTAGTAAC-3’ 
5’-TAGCTCCCTGCTTGCCTATACTATATGTTTTAATTG-3’ 
5’-GGCAAGCAGGGAGCTAGAAC-3’ 
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5’-GTGCCTATAGCTTTGTGTCCACAG-3’ 
 
pNL-GI-Tyr40.  Overlapping PCR was used to introduce amber mutations onto the GFP gene 
that is encoded on plasmid pNL-GI.[4]  The following primers are used to introduce the amber 
mutation: 
5’-GCTATAAGACGCGTCCACCATG-3’ 
5’-CCTAGGTGGCATCGCCCTC-3’ 
5’-CGATGCCACCTAGGGAAAGCTGACCCTGAAGTTC-3’ 
5’-CGTCTAGATTACTTGTACAGCTCATC-3’ 
 
Protein expression and purification.  293T cells were grown in media containing DMEM, 10% 
FBS (v/v), and 2 mM L-glutamine at 37 ºC in a humidified atmosphere of 5% CO2 (v/v).  When 
cells reached 60-70% confluency, they were transfected with plasmids pEGFP-40TAG and 
pAzFRS using Lipofectamine™ 2000 (Life Technologies) according to the manufacturer’s 
protocol (36 µL Lipofectamine + 12 µg of pAzFRS + 12 µg of pEGFP-TAG40 for 12 mL cell 
culture in 75 cm2 cell-culture flask).  Six hours posttransfection, the culture medium was 
carefully removed and replaced with 12ml of fresh medium containing 1 mM AzF.  Cells were 
grown for an additional 36 h before being washed with DPBS, lysed with RIPA buffer (Thermo 
Scientific), and partially purified using Ni-NTA resin (GE Healthcare) according to the 
manufacturer’s protocol. 
 
Transfection and generation of live HIV-1.  293T cells were grown in a medium containing 
DMEM, 10% FBS, and 2 mM L-glutamine at 37 ºC in a humidified atmosphere of 5% CO2.  
When cells reached 60-70% confluency, they were transfected with appropriate plasmid(s) 
using lipofectamine2000 (10 µl lipofectamine2000 + 3 µg of plasmid(s) for 2 ml cell culture in a 
6-well plate) by following standard procedures provided by the manufacture (Life Technologies).  
Six hours posttransfection, the culture medium was carefully removed and replaced with 2ml of 
fresh medium.  When it was needed, UAA* was added to a final concentration of 1 mM.  After 
44-48 hours of incubation, virus-containing culture supernatant was harvested by collecting the 
medium from the well using a pipette.  The FBS concentration in the virus-containing culture 
medium was then adjusted to 20% (i.e. for each 1ml of harvested virus, add 0.125 ml of FBS).  
The virus-containing culture medium was then filtered through a 0.45-micron filter.  The virus 
was used directly or aliquoted into sterile screw-cap vials and stored at − 80°C.  
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p24 assay.  P24 assay was measured with Retrotek HIV-1 p24 Antigen ELISA 2.0 by following 
standard procedures provided by the manufacture (ZeptoMetrix Corporation).  Briefly, 200 ml 
cell culture samples, the standard, and the control were added to the monoclonal antibody-
coated micro-plate wells and incubated at 37°C for 1.5 hour.  After washing and the addition of 
antibody-HRP conjugate, the micro-plate was incubated at 37°C for one hour.  Plates were then 
washed and the HRP-substrate was added for color development.  The reactions were stopped 
by the addition of 1 M H2SO4 and absorbance values were determined at 450 nm.  The amount 
of p24 is determined by interpolation from a point-to-point plot or from a linear regression 
analysis of the standard curve. 
 
Infection assay.  HIV-1 infection was quantified with X-gal staining based assay with TZM-bl 
cells.  Briefly, virus (generated in the presence of UAA*), 50 ml 10% DMEM growth medium, 
and DEAE-dextran at a final concentration of 40 mg/ml were added to each well (96-well flat 
bottom plate) that contains TZM-bl cells (1 × 104 per well in 100 ml volume) in triplicate.  Assay 
controls included: (1) replicate wells of TZM-bl cells with virus that are generated in the absence 
of UAA*; (2) growth medium only control; and (3) TZM-bl cell only control.  After 48-hour 
incubation at 37°C, 200 ml of assay medium was removed from each well.  Plates were then 
washed, fixed, and stained using X-gal solution followed by examination using a light 
microscope. 
 
Tissue Culture Infectious Dose 50 (TCID50).  Infectious titers of all viruses were determined 
by standard Tissue Culture Infectious Dose 50 (TCID50) method with X-gal staining assay (see 
above) in TZM-bl cells.  Briefly, four-fold serial dilutions of virus were performed in quadruplicate 
(96-well flat bottom plate) in the X-gal staining assay.  The TCID50 of the virus was calculated 
by Spearman-Karber formula according to the negative end-point and dilution folds. 
 
Fluorescence spectroscopy and cell imaging. The fluorescent images and bright-filed 
images were taken by a Nikon ECLIPSE TE3000 microscope and an EVOS FL Auto Imaging 
System with DIC.  The cells were excited at 488 nm to acquire EGFP fluorescence images at 
530/25 nm. 
 
LC/MS/MS.  The corresponding protein band of EGFP‐40TAG from SDS-PAGE was cut and 
in‐gel digested with trypsin (in 50 mM ammonium bicarbonate, pH 8.0) overnight at 37 °C.  The 
resulting peptide fragments were extracted with 0.1% formic acid/75% acetonitrile, and then 
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subjected to LC/MS/MS analysis using a Waters Q-TOF Ultima.  Database searches were 
performed on an in‐house Mascot server (Matrix Science Ltd., London, UK).  For AzF 
substitution site mapping on EGFP, AzF substitution for tyrosine was included as a variable 
modification. 
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Supplemental Figures. 
 
 
    
         Normalized OD values of above p24 assays 	  
well 1 well 4 well 7 
6.181 7.262 0.003 
well 2 well 5 well 8 
0.000 1.364 -0.009 
well 3 well 6 well 9 
0.785 3.201 1.912 
 
Figure S1.  p24 assay after transfection of 293T with pSUMA variants.   
1, wild-type pSUMA control; 2, negative ELISA control, no p24; 3, positive ELISA control, 125 
pg/ml p24; 4, pSUMA-Tyr132 + tRNATyr-AcFRS pair, with 1mM AcF; 5, pSUMA-Ala119 + 
tRNATyr-AcFRS pair, with 1mM AcF; 6, pSUMA-Leu365 + tRNATyr-AcFRS pair, with 1mM AcF; 
7, pSUMA-Tyr132 + tRNATyr-IodoFRS pair, with 1mM IodoF; 8, pSUMA-Ala119 + tRNATyr-
IodoFRS pair, with 1mM IodoF; 9, pSUMA-Leu365 + tRNATyr-IodoFRS pair, with 1mM IodoF.  
Well-2 was used as blank for p24 assays. 
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Figure S2.  Infection assays with TZM-bl cells using tRNATyr-AcFRS pair and tRNATyr-
IodoFRS pair.   
(A) infected with virus collected from pSUMA-Tyr132 + tRNATyr-AcFRS pair + 1mM AcF 
experiment; (B) infected with virus collected from pSUMA-Ala119 + tRNATyr-AcFRS pair + 1mM 
AcF experiment; (C) infected with virus collected from pSUMA-Leu365 + tRNATyr-AcFRS pair + 
1mM AcF experiment; (D) infected with virus collected from pSUMA-Tyr132 + tRNATyr-IodoFRS 
pair + 1mM IodoF; (E) infected with virus collected from pSUMA-Ala119 + tRNATyr-IodoFRS pair 
+ 1mM IodoF experiment; (F) infected with virus collected from pSUMA-Leu365 + tRNATyr-
IodoFRS pair + 1mM IodoF experiment.  Scale bars, 200 µm. 
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Figure S3.  Infection assays with TZM-bl cells using tRNATyr-AzFRS pair.   
(A) infected with virus collected from pSUMA-Ala119 + tRNATyr-AzFRS pair, without 1 mM AzF 
experiment; (B) infected with virus collected from pSUMA-Leu365 + tRNATyr-AzFRS pair, 
without 1mM AzF experiment; (C) Infected with pSUMA-Tyr59 + tRNATyr-AzFRS pair, without 1 
mM AzF experiment (the harvested viruses were concentrated 15 folds); (D) Infected with 
pSUMA-Trp36Gln127 + tRNATyr-AzFRS pair, without 1 mM AzF experiment (the harvested 
viruses were concentrated 15 folds).  Scale bars, 200 µm. 
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Figure S4.  Mass spectrometry analysis of EGFP containing AzF at position 40.   
The y ions are marked in the spectrum. The amino acid sequence of the peptide fragment, 
FSVSGEGEGDATAzFGK, from mutant EGFP containing AzF is shown on top.  The amber 
mutation site contained exclusively 4-aminophenylalanine (aminoF), which is the reduction 
product of AzF.  This observation is consistent with previous reports on the mass spectrometry 
analyses of AzF-containing proteins.[3,5] 
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